Published on 28 Jun 2023 on Simply Wall St. via Yahoo Finance
Institutions profited after Black Diamond Therapeutics, Inc.'s (NASDAQ:BDTX) market cap rose US$152m...
Key Insights
Significant control over Black Diamond Therapeutics by private equity firms implies that the general public has more power to influence management and governance-related decisionsThe top 5 shareholders own 54% of the company Institutions own 37% of Black Diamond Therapeutics
A look at the shareholders of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) can tell us which group is most powerful. We can see that private equity firms own the lion's share in the company with 40% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company.